Med-Chemist : "Quintessential Medicinal Chemistry"
Thursday, July 31, 2025
GLP-1 diabetes drugs likely trump metformin for curbing dementia risk in type 2 diabetes, study finds
›
In continuation of my update " Metformin " GLP-1 receptor agonists, a class of drug used to treat type 2 diabetes, likely trump t...
Friday, July 25, 2025
FDA Approves Ibtrozi (taletrectinib) for Advanced ROS1-Positive Non-Small Cell Lung Cancer
›
Nuvation Bio Inc. announced the U.S. Food and Drug Administration (FDA) approval of Ibtrozi (taletrectinib) for the treatment of adult pat...
Thursday, July 24, 2025
FDA Approves Zusduri (mitomycin) for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
›
UroGen Pharma Ltd. announced the U.S. Food and Drug Administration (FDA) approval of Zusduri, the first and only FDA-approved medication fo...
Monday, June 30, 2025
FDA Approves Symbravo (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults
›
Axsome Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approval of Symbravo (meloxicam and rizatripta...
Friday, June 27, 2025
FDA Approves Grafapex (treosulfan) Preparative Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
›
Medexus was informed that the FDA approved Grafapex, an alkylating agent, with fludarabine as a preparative regimen for allogeneic hematopoi...
Wednesday, June 25, 2025
FDA Approves Arbli (losartan potassium) Oral Suspension as the First Ready-to-Use Oral Liquid Losartan in the U.S.
›
In continuation of my update on losartan Scienture Holdings, Inc. announced the U.S. Food and Drug Administration (FDA) approval of SCN-1...
Monday, June 23, 2025
FDA Approves HemiClor (chlorthalidone) for the Treatment of Hypertension
›
PRM Pharma, LLC announced the U.S. Food and Drug Administration (FDA) approval of HemiClor (12.5 mg chlorthalidone) tablets for the treatme...
Friday, June 20, 2025
FDA Approves Blujepa (gepotidacin) for the Treatment of Uncomplicated Urinary Tract Infections
›
GSK plc announced the US Food and Drug Administration (FDA) approval of Blujepa (gepotidacin) for the treatment of female adults (≥40 kg) a...
Wednesday, June 18, 2025
FDA Approves Vykat XR (diazoxide choline) to Treat Hyperphagia in Prader-Willi Syndrome
›
Soleno Therapeutics, Inc. announced the U.S. Food and Drug Administration (FDA) approval of Vykat XR (diazoxide choline) extended-releas...
Monday, June 16, 2025
FDA Grants Accelerated Approval for Vanrafia (atrasentan) for Proteinuria Reduction in Primary IgA Nephropathy
›
Novartis announced the US Food and Drug Administration (FDA) accelerated approval for Vanrafia ® (atrasentan), a potent and selective end...
Saturday, June 14, 2025
FDA Approves Mezofy (aripiprazole) Oral Film for the Treatment of Schizophrenia
›
In continuation of my update on Aripiprazole CMG Pharmaceuticals, an affiliate of Cha Biotech, announced on the 16th that it had received pr...
Thursday, June 12, 2025
FDA Approves Atzumi (dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine
›
Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395), announced the U.S. Food and Drug Administration (FDA) approval of New Drug Applic...
Tuesday, October 8, 2024
FDA Approves Tepylute (thiotepa) Ready-to-Dilute Injectable Formulation to Treat Breast Cancer and Ovarian Cancer
›
Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA...
Monday, October 7, 2024
FDA Approves Ohtuvayre (ensifentrine) for the Maintenance Treatment of Chronic Obstructive Pulmonary Disease (COPD)
›
Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces the US Food and Drug Administration (“FDA”) approved Ohtuvayr...
‹
›
Home
View web version